Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc., a prominent player in the life sciences sector, is revolutionizing the field of proteomics. The company is known for its development and commercialization of the Proteograph Product Suite, an integrated solution designed to unlock deep, unbiased biological information. The suite comprises consumables, automation instrumentation, and software that enable comprehensive proteomic profiling and sample analysis, providing researchers with a detailed view of the proteome.
Seer's technology is built around proprietary engineered nanoparticles, which offer unmatched depth and scale in proteomic studies. This innovative approach allows for the detection of over 6,000 proteins and more than 55,000 peptide IDs in complex samples, such as plasma. The Proteograph Product Suite is designed for ease of use, with features like minimal hands-on time and fully automated workflows, making it accessible to a wide range of research labs.
The company primarily targets academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies, offering its products for non-diagnostic and non-clinical purposes. Seer has established significant collaborations with industry leaders like Discovery Life Sciences, Bruker Scientific LLC, and Thermo Electron North America LLC, enhancing its market reach and technological capabilities.
Recently, Seer has made headlines through its partnership with Panome Bio to integrate deep, unbiased proteomics with metabolomics, aiming to accelerate research in biomarker discovery and drug development. The collaboration is expected to facilitate groundbreaking studies with robust pathway analyses, significantly advancing the understanding of biology and disease.
In another noteworthy development, Seer announced a major study published in Nature Communications, conducted in collaboration with Weill Cornell Medicine. This research showcased Seer's Proteograph workflow's potential to unveil novel proteogenomic insights, linking genetic variation with protein abundance at peptide level resolution. This study is a testament to Seer's commitment to advancing multi-omics research and enhancing precision medicine.
Seer's financial outlook remains optimistic despite macroeconomic challenges. The company continues to drive the adoption of its Proteograph Product Suite by expanding its Technology Access Center and increasing its commercial reach. As more customer data and third-party publications highlight the power of Seer's technology, the company anticipates growing adoption and impact in the scientific community.
In summary, Seer, Inc. is at the forefront of proteomics, offering transformative solutions that provide unparalleled insights into the proteome, thus paving the way for significant advancements in biological research and precision medicine.
Seer Inc. (NASDAQ: SEER) has officially launched the Proteograph Product Suite, which promises revolutionary advancements in proteomics, akin to next-generation sequencing in genomics. The suite employs proprietary engineered nanoparticles, enabling rapid and unbiased proteomics analysis. Seer has secured multiple orders for this product and initiated its Centers of Excellence program, partnering with leading service providers globally to facilitate the technology's adoption. Key partners include Biodesix and Discovery Life Sciences, enhancing service accessibility in major geographies.
Seer Inc. (NASDAQ: SEER), SCIEX, and Discovery Life Sciences have formed the Proteogenomics Consortium to enhance proteomics analysis for genomics research. This collaboration aims to analyze over 1 billion peptides annually, enabling the discovery of new protein variants and biomarkers. The Proteograph Product Suite and SCIEX ZenoTOF 7600 will provide deep, unbiased proteomics capabilities. The consortium is positioned to accelerate research in human health and disease, significantly expanding proteomic studies across various cohorts.
Seer Inc. (NASDAQ: SEER) has announced the broad commercial release of its Proteograph Product Suite, which facilitates unbiased and rapid proteomics. The product suite has garnered multiple orders and includes engineered nanoparticles, automated instrumentation, and software for deep proteomics studies. Seer's new Centers of Excellence program aims to accelerate the adoption of this technology by partnering with leading service providers worldwide. These developments position Seer as a leader in innovative proteomics solutions, enhancing research capabilities across various regions.
Seer, Inc. (Nasdaq: SEER) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. The management team is scheduled to present at 8:15 a.m. Pacific Time and will hold a Q&A session. A live webcast will be available on Seer's investor website, with an archived replay accessible afterward.
Seer specializes in developing products for proteomic analysis, including the Proteograph™ Product Suite, designed for deep and unbiased analysis in a streamlined manner. This product is intended for research use only.
Seer, Inc. (Nasdaq: SEER) has appointed Meeta Gulyani to its Board of Directors. Gulyani, currently Executive Vice President at Merck KGaA, brings extensive experience in life sciences. Her leadership is expected to support Seer's mission in proteomics, which aims to unlock new insights in healthcare. Gulyani has held significant roles at Roche and possesses a strong background in strategy, business development, and transformation. Seer's Proteograph Product Suite is at the forefront of proteomic analysis, enhancing research capabilities in various laboratories.
Seer, a life sciences company listed on Nasdaq as SEER, announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded presentation will be available online starting November 22, 2021. Additionally, Seer will conduct investor meetings on December 1 and 2, 2021. The company is focused on its Proteograph Product Suite, designed for efficient and deep proteomic analysis, accessible to many laboratories. The suite is for research use only and not intended for diagnostic procedures.
Seer, Inc. reported third-quarter 2021 revenues of $2.2 million, a significant increase from $72,000 in Q3 2020, driven by the Proteograph Product Suite. Product-related revenue reached $1.6 million, with a gross profit of $1.2 million and a gross margin of 54%. However, the company's operating expenses surged to $19.6 million, resulting in a net loss of $18.4 million. As of September 30, 2021, Seer held approximately $506.6 million in cash and investments. The company is on track for a Broad Release of its product in early 2022.
Seer, Inc. (Nasdaq: SEER) has appointed Rachel Haurwitz, Ph.D., CEO of Caribou Biosciences, to its Board of Directors effective November 8, 2021. Haurwitz's extensive experience in genome editing is expected to bolster Seer's mission in proteomics. David Singer will step down from the board, marking a significant leadership transition. The addition of Haurwitz, a recognized figure in the biotechnology field, reflects Seer’s commitment to advancing its innovative Proteograph technology aimed at enhancing biological insights.
Seer, Inc. (Nasdaq: SEER) will announce its Q3 2021 financial results on November 9, 2021, after market close, followed by a conference call at 1:30 p.m. PT. The company is known for its innovative Proteograph™ Product Suite, designed for advanced proteomic analysis. This system utilizes proprietary nanoparticles and automation to facilitate in-depth research quickly and efficiently. The results and details will be accessible via Seer’s investor website.
Seer, a life sciences company specializing in proteomics, announced its participation in the Morgan Stanley Global Healthcare Conference. The virtual fireside chat is scheduled for September 9 at 9:30 a.m. Pacific Time. A live webcast will be accessible on Seer's investor website, with an archived replay available post-conference. Seer’s Proteograph Product Suite provides deep proteomic analysis using innovative technology to enhance research capabilities across various labs. This product is intended for research use only and not for diagnostic procedures.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is Seer, Inc. known for?
What does the Proteograph Product Suite include?
Who are Seer's primary customers?
What recent collaborations has Seer announced?
What are the benefits of Seer's proprietary engineered nanoparticles?
What was the focus of Seer's recent study published in Nature Communications?
What is Seer's strategy to drive adoption of its technology?
Is the Proteograph Product Suite intended for diagnostic use?
Where is Seer, Inc. headquartered?
What potential does Seer see in its technology?
